Inhibikase Therapeutics Inc. announced the election of Dr. Hilary Malone, current Chief Regulatory Officer, Sanofi, to its Board of Directors. Dr. Steven R. Gilman has retired from the Board after nearly four-and-one-half years of service. Prior to joining Sanofi, Dr. Malone held roles as the Senior Vice-President and Head of Worldwide Regulatory Strategy for both Pfizer and Wyeth.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.84 USD | +1.66% | +1.66% | +44.88% |
05-21 | HC Wainwright Adjusts Inhibikase Therapeutics Price Target to $23 From $27, Maintains Buy Rating | MT |
05-16 | Transcript : Inhibikase Therapeutics, Inc., Q1 2024 Earnings Call, May 16, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+44.88% | 13.23M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- IKT Stock
- News Inhibikase Therapeutics, Inc.
- Inhibikase Therapeutics, Inc. Announces Board Changes